Vertex says Phase III data highlight suzetrigine’s potential

Vertex Pharmaceuticals (Nasdaq: VRTX) on Sunday presented its pivotal Phase III data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from Philadelphia, Pennsylvania.

This was the first time the suzetrigine Phase III data were presented to the medical community following the January 2024 announcement that the Phase III trials were positive. The Phase III program included two randomized, double-blind, placebo-controlled trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical and non-surgical pain conditions.

Vertex said that results from all three studies demonstrate compelling and consistent efficacy and safety across multiple acute pain conditions and settings.